Exosomal microRNA in peritoneal fluid as a biomarker of peritoneal metastases from gastric cancer.

biomarker exosome intraperitoneal chemotherapy microRNA peritoneal metastasis

Journal

Annals of gastroenterological surgery
ISSN: 2475-0328
Titre abrégé: Ann Gastroenterol Surg
Pays: Japan
ID NLM: 101718062

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 06 09 2019
revised: 09 10 2019
accepted: 11 10 2019
entrez: 6 2 2020
pubmed: 6 2 2020
medline: 6 2 2020
Statut: epublish

Résumé

Peritoneal metastases (PM) frequently occur in patients with gastric cancer and result in a poor prognosis. Exosomes play pivotal roles in tumor metastasis through the transfer of microRNAs (miRNAs). We examined the exosomal miRNA profile in peritoneal fluids to identify novel biomarkers to reflect tumor burden in the peritoneum. Exosomes were isolated from peritoneal fluids of patients of gastric cancer with macroscopic (P1) or microscopic (P0CY1) peritoneal metastasis (PM) and comprehensive miRNA expression analysis was carried out. Expressions of candidate miRNAs were then validated in all 58 samples using TaqMan Advanced miRNA Assays. In initial screening, we carried out comprehensive analysis of exosomal miRNA using peritoneal fluids from 11 and 14 patients with or without PM, respectively, and identified 11 dysregulated miRNAs in PM (+) samples. Validation analysis showed that four miRNAs (miR-21-5p, miR-92a-3p, miR-223-3p, and miR-342-3p) were significantly upregulated in 12 PM (+) samples, and their expression levels showed positive correlation with peritoneal cancer index. In contrast, miR-29 family were all downregulated in patients with PM (+) samples. Moreover, in 24 patients with pT4 tumor, miR-29 at gastrectomy tended to be lower in six patients with peritoneal recurrence with significant differences in miR-29b-3p ( Expression pattern of miRNAs in peritoneal exosomes well reflects the tumor burden in the peritoneal cavity and could be a useful biomarker in the treatment of PM.

Identifiants

pubmed: 32021962
doi: 10.1002/ags3.12296
pii: AGS312296
pmc: PMC6992685
doi:

Types de publication

Journal Article

Langues

eng

Pagination

84-93

Informations de copyright

© 2019 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterology.

Déclaration de conflit d'intérêts

Funding: This work was supported by a Japan Society for the Promotion of Science (17H04286). Conflicts of Interest: Authors declare no conflicts of interest for this article.

Références

Int J Clin Exp Med. 2015 Sep 15;8(9):16890-8
pubmed: 26629240
Cancer Lett. 2016 Jun 1;375(2):331-339
pubmed: 27000664
BMC Cancer. 2014 Nov 07;14:819
pubmed: 25376700
Am J Respir Cell Mol Biol. 2011 Aug;45(2):287-94
pubmed: 20971881
Lab Invest. 2014 Sep;94(9):978-90
pubmed: 25046436
Cancer Gene Ther. 2017 Feb;24(2):48-56
pubmed: 27982021
PLoS One. 2015 Apr 15;10(4):e0123926
pubmed: 25874772
Am J Transl Res. 2014 Jul 18;6(4):391-401
pubmed: 25075256
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
Cancer Med. 2014 Aug;3(4):878-88
pubmed: 24902858
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Ann Gastroenterol Surg. 2018 Feb 16;2(2):116-123
pubmed: 29863151
Biomarkers. 2019 Mar;24(2):110-119
pubmed: 30387681
Oncotarget. 2017 Jun 27;8(26):42262-42271
pubmed: 28178689
Carcinogenesis. 2014 Feb;35(2):497-506
pubmed: 24130168
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
pubmed: 16461460
Cell Physiol Biochem. 2015;35(3):933-44
pubmed: 25633747
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Radiology. 2009 Nov;253(2):407-15
pubmed: 19789243
Nat Rev Genet. 2009 Oct;10(10):704-14
pubmed: 19763153
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13027-32
pubmed: 18723672
J BUON. 2014 Jan-Mar;19(1):228-36
pubmed: 24659669
Oncogene. 2007 Sep 13;26(42):6133-40
pubmed: 17404574
PLoS One. 2015 Jul 24;10(7):e0130472
pubmed: 26208314
J Transl Med. 2011 Jun 08;9:86
pubmed: 21651777
Mol Cancer Res. 2011 Jul;9(7):824-33
pubmed: 21628394
J Cancer. 2019 Jan 29;10(5):1181-1188
pubmed: 30854127
FEBS Lett. 2017 Jul;591(14):2167-2179
pubmed: 28643334
World J Gastrointest Oncol. 2017 Mar 15;9(3):121-128
pubmed: 28344747
Exp Ther Med. 2018 May;15(5):4179-4184
pubmed: 29725366

Auteurs

Hideyuki Ohzawa (H)

Center for Clinical Research Jichi Medical University Hospital Shimotsuke Japan.

Yuko Kumagai (Y)

Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.

Hironori Yamaguchi (H)

Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.
Department of Clinical Oncology Jichi Medical University Shimotsuke Japan.

Hideyo Miyato (H)

Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.

Yasunaru Sakuma (Y)

Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.

Hisanaga Horie (H)

Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.

Yoshinori Hosoya (Y)

Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.

Alan Kawarai Lefor (A)

Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.

Naohiro Sata (N)

Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.

Joji Kitayama (J)

Center for Clinical Research Jichi Medical University Hospital Shimotsuke Japan.
Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.

Classifications MeSH